Contemporary medical therapy for polycystic ovary syndrome

International Journal of Gynecology and Obstetrics

Volumn 95, Issue 3, 2006, Pages 236-241

  Lanham, M S M ^a   Lebovic, D I ^a   Domino, S E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Insulin resistance; Insulin sensitizing medicines; Polycystic ovaries

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ANTIANDROGEN; AROMATASE INHIBITOR; CLOMIFENE CITRATE; COMPACTIN; CYPROTERONE ACETATE; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; EFLORNITHINE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LETROZOLE; METFORMIN; ORAL CONTRACEPTIVE AGENT; ORNITHINE DECARBOXYLASE INHIBITOR; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TROGLITAZONE; YAZ;

ABDOMINAL DISCOMFORT; ACNE; ANOREXIA; ANOVULATION; ARTHRALGIA; ARTHRITIS; BIOCHEMISTRY; CLINICAL TRIAL; CONSENSUS; CONSERVATIVE TREATMENT; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DIARRHEA; DIATHERMY; DRUG MEGADOSE; DRUG POTENTIATION; ENDOMETRIUM HYPERPLASIA; ENVIRONMENTAL FACTOR; ESTHETIC SURGERY; FEMALE INFERTILITY; GALEGA OFFICINALIS; GONADAL DISEASE; HAIR DISEASE; HAIR FOLLICLE; HAIR GROWTH; HEREDITY; HIRSUTISM; HOT FLUSH; HUMAN; HYPERANDROGENISM; HYPOSPADIAS; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; MEDICINAL PLANT; MENSTRUAL IRREGULARITY; METRORRHAGIA; MYALGIA; NAUSEA; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIODIAGNOSIS; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; VARIANCE; WEIGHT REDUCTION;

EID: 33750819158     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2006.08.004     Document Type: Review

References (46)

1. Battaglia C. The role of ultrasound and Doppler analysis in the diagnosis of polycystic ovary syndrome. Ultrasound Obstet Gynecol 22 (2003) 225-232
2. Stein I., and Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29 (1935) 181-191
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
4. Farquhar C.M., Birdsall M., Manning P., Mitchell J.M., and France J.T. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 34 (1994) 67-72
5. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
6. Lowe P., Kovacs G., and Howlett D. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Aust N Z J Obstet Gynaecol 45 (2005) 17-19
7. Balen A.H. Polycystic ovary syndrome: a guide to clinical management (2005), Taylor & Francis, London 210 pp.
8. Legro R.S., Spielman R., Urbanek M., Driscoll D., Strauss III J.F., and Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 53 (1998) 217-256
9. Franks S., Gharani N., and McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 7 (2001) 405-410
10. Sam S., Legro R.S., Essah P.A., Apridonidze T., and Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 103 (2006) 7030-7035
11. Dunaif A., Xia J., Book C.B., Schenker E., and Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96 (1995) 801-810
12. Arslanian S.A., Lewy V., Danadian K., and Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87 (2002) 1555-1559
13. Willis D.S., Watson H., Mason H.D., Galea R., Brincat M., and Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab 83 (1998) 3984-3991
14. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med 352 (2005) 1223-1236
15. Kiddy D.S., Hamilton-Fairley D., Bush A., Short F., Anyaoku V., Reed M.J., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 (1992) 105-111
16. ACOG Committee on Practice Bulletins-Gynecology. Clinical Management Guidelines for Obstetrician-Gynecologists Number 34, February 2002. Management of infertility caused by ovulatory dysfunction. Obstet Gynecol 99 (2002) 347-358
17. Farquhar C.M., Williamson K., Brown P.M., and Garland J. An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate resistant polycystic ovary syndrome. Hum Reprod 19 (2004) 1110-1115
18. Diamanti-Kandarakis E., Baillargeon J.P., Iuorno M.J., Jakubowicz D.J., and Nestler J.E. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88 (2003) 1927-1932
19. Vrbikova J., and Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11 (2005) 277-291
20. Golland I.M., and Elstein M.E. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci 687 (1993) 263-271
21. Batukan C., and Muderris I.I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 85 (2006) 436-440
22. Young R.L., Goldzieher J.W., and Elkind-Hirsch K. The endocrine effects of spironolactone used as an antiandrogen. Fertil Steril 48 (1987) 223-228
23. Muderris I.I., Bayram F., and Guven M. Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 14 (2000) 38-41
24. Falsetti L., Gambera A., Legrenzi L., Iacobello C., and Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 141 (1999) 361-367
25. Balfour J.A., and McClellan K. Topical eflornithine. Am J Clin Dermatol 2 (2001) 197-201 [discussion 2]
26. Hobbs L., Ort R., and Dover J. Synopsis of laser assisted hair removal systems. Skin Therapy Lett 5 (2000) 1-5
27. Moran L.J., Noakes M., Clifton P.M., Tomlinson L., Galletly C., and Norman R.J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 812-819
28. Nestler J.E., Jakubowicz D.J., Evans W.S., and Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338 (1998) 1876-1880
29. Kousta E., White D.M., and Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 3 (1997) 359-365
30. Vandermolen D.T., Ratts V.S., Evans W.S., Stovall D.W., Kauma S.W., and Nestler J.E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75 (2001) 310-315
31. Casper R.F., and Mitwally M.F. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91 (2006) 760-771
32. Sohrabvand F., Ansari S., and Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod 21 (2006) 1432-1435
33. Witters L.A. The blooming of the French lilac. J Clin Invest 108 (2001) 1105-1107
34. Stumvoll M., Nurjhan N., Perriello G., Dailey G., and Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333 (1995) 550-554
35. Harborne L.R., Sattar N., Norman J.E., and Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 90 (2005) 4593-4598
36. Glueck C.J., Goldenberg N., Pranikoff J., Loftspring M., Sieve L., and Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 19 (2004) 1323-1330
37. Lord J.M., Flight I.H., and Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev (2003) CD003053
38. Eisenhardt S., Schwarzmann N., Henschel V., Germeyer A., von Wolff M., Hamann A., et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 91 (2006) 946-952
39. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., Roberts K.A., and Nestler J.E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 524-549
40. Khorram O., Helliwell J.P., Katz S., Bonpane C.M., and Jaramillo L. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertil Steril 85 (2006) 1448-1451
41. Davis S. Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the Endocrine Pancreas. In: Goodman L.S., Gilman A., Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's the pharmacological basis of therapeutics (2006), McGraw-Hill, New York 1613-1646
42. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
43. Ghazeeri G., Kutteh W.H., Bryer-Ash M., Haas D., and Ke R.W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79 (2003) 562-566
44. Rouzi A.A., and Ardawi M.S. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 85 (2006) 428-435
45. Izquierdo D., Foyouzi N., Kwintkiewicz J., and Duleba A.J. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 82 Suppl 3 (2004) 1193-1197
46. Duleba A.J., Banaszewska B., Spaczynski R.Z., and Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 85 (2006) 996-1001